Search Results - Toshifumi Yokota
Toshifumi Yokota
Toshifumi (Toshi) Yokota () is a biomedical scientist and professor of medical genetics at the University of Alberta, holding the titles of the Friends of Garrett Cumming Research & Muscular Dystrophy Canada Endowed Research Chair and the Henri M. Toupin Chair in Neurological Science. Yokota is widely recognized for pioneering work in antisense therapy for muscular dystrophy and other genetic diseases, which led to the development of viltolarsen, an FDA-approved treatment for Duchenne muscular dystrophy (DMD). With over 100 peer-reviewed publications and several patents, Yokota has made significant contributions to the field of precision medicine. Yokota also co-edited three volumes in the Methods in Molecular Biology series by Humana Press, Springer-Nature and is on editorial boards of multiple scientific journals.In 2023, Yokota was elected as a fellow of the Canadian Academy of Health Sciences, an honor that recognizes outstanding achievements in health sciences. In addition, Yokota is Chief Scientific Officer at OligomicsTx, is a co-founder of the Canadian Neuromuscular Network (CAN-NMD), and contributes as a member of the Medical and Scientific Advisory Committee of Muscular Dystrophy Canada. Provided by Wikipedia
- Showing 1 - 7 results of 7
-
1
Genetic Approaches for the Treatment of Facioscapulohumeral Muscular Dystrophy by Kenji Rowel Q. Lim, Toshifumi Yokota, Toshifumi Yokota
Published 2021Call Number: Loading…Connect to this object online.
Located: Loading…
Book -
2
Recent Trends in Antisense Therapies for Duchenne Muscular Dystrophy by Harry Wilton-Clark, Toshifumi Yokota
Published 2023Call Number: Loading…Connect to this object online.
Located: Loading…
Book -
3
Enhancing the Effectiveness of Oligonucleotide Therapeutics Using Cell-Penetrating Peptide Conjugation, Chemical Modification, and Carrier-Based Delivery Strategies by Saeed Anwar, Farin Mir, Toshifumi Yokota
Published 2023Call Number: Loading…Connect to this object online.
Located: Loading…
Book -
4
Identification of Novel Antisense-Mediated Exon Skipping Targets in DYSF for Therapeutic Treatment of Dysferlinopathy by Joshua J.A. Lee, Rika Maruyama, William Duddy, Hidetoshi Sakurai, Toshifumi Yokota
Published 2018Call Number: Loading…Connect to this object online.
Located: Loading…
Book -
5
Ensemble-Learning and Feature Selection Techniques for Enhanced Antisense Oligonucleotide Efficacy Prediction in Exon Skipping by Alex Zhu, Shuntaro Chiba, Yuki Shimizu, Katsuhiko Kunitake, Yasushi Okuno, Yoshitsugu Aoki, Toshifumi Yokota
Published 2023Call Number: Loading…Connect to this object online.
Located: Loading…
Book -
6
Long-Term Efficacy of Systemic Multiexon Skipping Targeting Dystrophin Exons 45-55 With a Cocktail of Vivo-Morpholinos in Mdx52 Mice by Yusuke Echigoya, Yoshitsugu Aoki, Bailey Miskew, Dharminder Panesar, Aleksander Touznik, Tetsuya Nagata, Jun Tanihata, Akinori Nakamura, Kanneboyina Nagaraju, Toshifumi Yokota
Published 2015Call Number: Loading…Connect to this object online.
Located: Loading…
Book -
7
Scavenger Receptor Class A1 Mediates Uptake of Morpholino Antisense Oligonucleotide into Dystrophic Skeletal Muscle by Shouta Miyatake, Yoshitaka Mizobe, Maria K. Tsoumpra, Kenji Rowel Q. Lim, Yuko Hara, Fazel Shabanpoor, Toshifumi Yokota, Shin'ichi Takeda, Yoshitsugu Aoki
Published 2019Call Number: Loading…Connect to this object online.
Located: Loading…
Book